Clinical Trial Search

Primary: Percent of Participants Who Have an Individual Counseling Session About PrEP. — 28; 28 Participants — p=1.0

Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms, After Each Vaccine Dose — 0; 0; 0; 8 Participants

Primary: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf) of ARV-471 — 18960; 32020 nanogram*hour per milliliter (ng*hr/mL)

Primary: Area Under the Plasma Concentration-time Curve up to 30 Minutes Post-dose (AUC (0-30 Min)) of Salbutamol — 0.622; 0.536 Hour*nanogram/milliliter (h*ng/mL)

Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Lotiglipron When Administered Alone and With Itraconazole or Cyclosporine — 81800; 162800…

Primary: Area Under the Time-Concentration Curve From the Start of Dosing to 63 Days (AUC0-62) for Serum Pertuzumab — 1671.2; 1674.6 μg*day/mL

Primary: Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) for Bosutinib — 591.3; 591.7; 479.4 nanogram*hour per milliliter (ng*hr/mL)

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs): Part 1 — 3; 0; 1; 2 Participants

Primary: Change in the Biomarker (PD-L1) Expression — 11; 12; 0; 0 Participants — p=1.0

Primary: Blood Loss — 122.6; 133.3 cubic centimeters

Primary: Steady State Plasma Concentrations of Doravirine After Drug Intake Cessation up to 72 Hours Post-dose. — 18354; 26338 ng*hr/mL

Primary: Number of Participants With Grade 2 or Higher (>=) Adverse Events (AEs) Following SC Administration of VH3810109 (Part 1 and Part 3) — 7; 8 Participants

Primary: Predose and Postdose Plasma Certolizumab Pegol (CZP) Concentrations in Women During Pregnancy, Relative to Postpartum — 15.251; NA; 16.916; 9.027 microgram per…

Primary: Safety and Tolerability of Fostamatinib — 0; 0; 1 Dose Limiting Toxicities (DLTs)

Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 Participants